A Phase 3 Study of Pacritinib in Patients with Myelofibrosis

• Research type

  Research Study

• Full title

  A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

• IRAS ID

  119349

• Contact name

  Adam Mead

• Contact email

  adam.mead@imm.ox.ac.uk

• Sponsor organisation

  CTI BioPharma Corp.

• Eudract number

  2012-004239-21

• Clinicaltrials.gov Identifier

  NCT01773187

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  13/LO/0535

• Date of REC Opinion

  25 Apr 2013

• REC opinion

  Further Information Favourable Opinion